ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Ranbaxy Ends Pact With Japanese Partner

by Jean-François Tremblay
December 14, 2009 | APPEARED IN VOLUME 87, ISSUE 50

Ranbaxy Laboratories has agreed to sell partner Nihon Chemiphar its 50% stake in their Japanese joint venture, Nihon Pharmaceutical Industry. Chemiphar is a Japan-based developer and manufacturer of generic drugs. The companies did not explain whether the dissolution is linked to the 2008 acquisition of Ranbaxy by Daiichi Sankyo, one of Chemiphar’s competitors in Japan. To ensure a smooth transition, Ranbaxy will supply drugs made in India to Nihon for a limited time.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment